Cinacalcet therapy in patients affected by primary hyperparathyroidism associated to Multiple Endocrine Neoplasia Syndrome type 1 (MEN1)

Published on Jun 1, 2016in Endocrine3.235
· DOI :10.1007/S12020-015-0696-5
Francesca Giusti15
Estimated H-index: 15
(UniFI: University of Florence),
Luisella Cianferotti27
Estimated H-index: 27
(UniFI: University of Florence)
+ 6 AuthorsMaria Luisa Brandi88
Estimated H-index: 88
(UniFI: University of Florence)
Primary hyperparathyroidism is the main endocrinopathy associated with Multiple Endocrine Neoplasia type 1 syndrome. Cinacalcet is a calcimimetic agent licensed for the treatment of secondary hyperparathyroidism in patients with end-stage renal disease, and for the reduction of marked hypercalcemia in patients with parathyroid carcinoma and sporadic hyperparathyroidism requiring surgery but for whom parathyroidectomy is contraindicated. It may provide a medical alternative for the management of primary hyperparathyroidism in subjects affected by Multiple Endocrine Neoplasia type 1. In this longitudinal, intervention study, 33 MEN1 patients had been enrolled, 10 males and 23 females with a mean age of 40 ± 11.9 years, range 20–63. Primary hyperparathyroidism was the first clinical manifestation in 12 patients. All subjects commenced with Cinacalcet 30 mg/day, 22 patients starting therapy with calcimimetics as an alternative to surgery, and 11 patients opting for the medication after the onset of persistent post-surgical primary hyperparathyroidism. Duration of follow-up was 12 months. The results of this study show significant reductions in serum calcium. The changes in hormonal secretions of pituitary and gastroenteropancreatic glands were not significant, demonstrating the overall safety of this drug in this disease. Cinacalcet has been well tolerated by 28 patients, whereas five individuals complained of heartburn and grade 1 nausea, which did not prevent the completion of the study. In conclusion, Cinacalcet has resulted to be well tolerated and safe in patients with MEN1 syndrome and the calcium homeostasis was stabilized.
📖 Papers frequently viewed together
672 Citations
67 Citations
5 Citations
#1Aliya KhanH-Index: 41
#2John P. BilezikianH-Index: 122
Last. Miklós TóthH-Index: 54
view all 9 authors...
Objective: Primary hyperparathyroidism (PHPT) is diagnosed by the presence of hypercalcemia and elevated or nonsuppressed parathyroid hormone (PTH) levels. Although surgery is usually curative, some individuals fail or are unable or unwilling to undergo parathyroidectomy. In such individuals, targeted medical therapy may be of value. Cinacalcet normalized calcium level and lowered PTH in patients with PHPT in several phase 2 and open-label studies. We compared cinacalcet and placebo in subjects ...
23 CitationsSource
#1Claudio Marcocci (UniPi: University of Pisa)H-Index: 73
#2Jens Bollerslev (Oslo University Hospital)H-Index: 63
Last. Dolores M. Shoback (SFVAMC: San Francisco VA Medical Center)H-Index: 55
view all 4 authors...
Objective: Asymptomatic primary hyperparathyroidism (PHPT) is a common clinical problem. The only available definitive therapy is parathyroidectomy, which is appropriate to consider in all patients. The purpose of this report is to provide an update on calcium and vitamin D supplementation and medical management for those patients with PHPT who cannot or do not want to undergo surgery. Methods: Questions were developed by the International Task Force on PHPT. A comprehensive literature search wa...
97 CitationsSource
#1Valeria RamundoH-Index: 18
#2M. Del PreteH-Index: 6
Last. Antongiulio FaggianoH-Index: 52
view all 14 authors...
SummaryBackground Somatostatin analogues (SSA) represent one of the main therapeutic option in patients affected with functioning well-differentiated neuroendocrine tumours (NETs). There are no studies specifically focusing on NETs associated with Multiple Endocrine Neoplasia type 1 (MEN1). Aim To evaluate the efficacy of the long-acting SSA octreotide in MEN1 patients with early-stage duodeno-pancreatic NETs. Patients and Methods Forty patients with MEN1 were retrospectively evaluated. Twenty p...
27 CitationsSource
#1Federica Saponaro (UniPi: University of Pisa)H-Index: 16
Last. Claudio Marcocci (UniPi: University of Pisa)H-Index: 73
view all 18 authors...
SummaryObjective To report the Italian experience on cinacalcet use following its approval by the European Medical Agency (EMA) to control hypercalcaemia in patients with primary hyperparathyroidism (PHPT). Design Retrospective data collection from 100 patients with sporadic (sPHPT) and 35 with familial PHPT (fPHPT) followed in eight Italian centres between October 2008 and March 2011. Measurements Albumin-adjusted serum calcium, PTH, 25OHD, daily cinacalcet dose and adverse events were recorded...
23 CitationsSource
Abstract Primary hyperparathyroidism (PHPT) is the most common cause of hypercalcemia in the outpatient population. It is diagnosed in most individuals in the Western world at an asymptomatic stage without signs or symptoms of parathyroid hormone (PTH) calcium excess. Nonspecific symptoms include weakness, malaise, fatigue, and possible mood disturbances, which may be present at the time of diagnosis. The diagnosis of PHPT is confirmed in the presence of hypercalcemia and a normal or elevated PT...
31 CitationsSource
#1Rajesh V. Thakker (University of Oxford)H-Index: 95
#2Paul J Newey (University of Oxford)H-Index: 13
Last. Maria Luisa Brandi (UniFI: University of Florence)H-Index: 88
view all 10 authors...
Objective: The aim was to provide guidelines for evaluation, treatment, and genetic testing for multiple endocrine neoplasia type 1 (MEN1). Participants: The group, which comprised 10 experts, including physicians, surgeons, and geneticists from international centers, received no corporate funding or remuneration. Process: Guidelines were developed by reviews of peer-reviewed publications; a draft was prepared, reviewed, and rigorously revised at several stages; and agreed-upon revisions were in...
672 CitationsSource
#1Marcello FilopantiH-Index: 19
#2Uberta Verga (Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico)H-Index: 4
Last. Anna Spada (Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico)H-Index: 70
view all 9 authors...
Objective: Primary hyperparathyroidism (PHPT) is a challenging problem in type 1 multiple endocrine neoplasia (MEN1) due to the high postsurgery recurrence rate. The aim was to evaluate the efficacy of cinacalcet in MEN1 patients in comparison with patients with sporadic PHPT (sPHPT) and the effect of Arg990Gly calcium-sensing receptor (CASR) polymorphism on the response to treatment. Design: This is a randomized, crossover, double-blind study carried out in the University Hospitals. Methods: Fi...
35 CitationsSource
#1B TinkleH-Index: 1
#2N LeslieH-Index: 1
109 Citations
#1Désirée Haid (University of Hohenheim)H-Index: 6
#2Patricia Widmayer (University of Hohenheim)H-Index: 13
Last. Heinz Breer (University of Hohenheim)H-Index: 80
view all 3 authors...
Sensing protein breakdown products in the luminal content is of particular importance for the regulation of digestive activities in the stomach which are mainly governed by gastric hormones. The molecular basis for tuning the release of hormones according to the protein content is still elusive. In this study we have analysed the murine stomach for candidate nutrient receptors. As a promising candidate we have concentrated on the broadly tuned amino acid receptor GPRC6A. Expression of GPRC6A cou...
43 CitationsSource
#1Yasuo Imanishi (OCU: Osaka City University)H-Index: 28
#2Takehisa Kawata (OCU: Osaka City University)H-Index: 9
Last. Masaaki Inaba (OCU: Osaka City University)H-Index: 77
view all 8 authors...
Cinacalcet HCl (cinacalcet) is a calcimimetic compound, which suppresses parathyroid (PTH) hormone secretion from parathyroid glands in both primary hyperparathyroidism (PHPT) and secondary hyperparathyroidism (SHPT). We previously reported the suppressive effect of cinacalcet on PTH secretion in vivo in a PHPT model mouse, in which parathyroid-targeted overexpression of the cyclinD1 oncogene caused chronic biochemical hyperparathyroidism and parathyroid cell hyperplasia. Although cinacalcet sup...
19 CitationsSource
Cited By26
#1A. GeslotH-Index: 1
#2M. VialonH-Index: 3
Last. Delphine VezzosiH-Index: 15
view all 5 authors...
Abstract In 1953, for the first time, Paul Wermer described a family presenting endocrine gland neoplasms over several generations. The transmission was autosomal dominant and the penetrance was high. Forty years later in 1997, the Multiple Endocrine Neoplasia type 1 (MEN1) gene was sequenced, thus enabling diagnosis and early optimal treatment. Patients carrying the MEN1 gene present endocrine but also non-endocrine tumors. Parathyroid, pancreatic and pituitary impairment are the three main typ...
Abstract Purpose In patients with primary hyperparathyroidism (PHPT) and severe hypercalcemia, parathyroidectomy remains the only curative therapy. During the coronavirus disease 2019 (COVID-19) pandemic, when many hospital visits are suspended and surgeries cannot be performed, the management of these patients represents a challenging clinical situation. This article presents a literature review and discussion of the pharmacologic management of PHPT and severe hypercalcemia, which can be used a...
#1A. Al-SalamehH-Index: 4
Last. Philippe Chanson (Université Paris-Saclay)H-Index: 94
view all 5 authors...
Multiple endocrine neoplasia type 1 (MEN1) is a rare syndrome characterized by the co-occurrence of primary hyperparathyroidism, duodenopancreatic neuroendocrine tumours (NETs) and/or pituitary adenomas. MEN1 can predispose patients to other endocrine and non-endocrine tumours, such as cutaneous tumours, central nervous system tumours and breast cancer. Endocrine tumours in patients with MEN1 differ from sporadic tumours in that they have a younger age at onset, present as multiple tumours in th...
#1Francesca Marini (UniFI: University of Florence)H-Index: 23
#2Francesca Giusti (UniFI: University of Florence)H-Index: 15
Last. Maria Luisa Brandi (UniFI: University of Florence)H-Index: 88
view all 4 authors...
Multiple endocrine neoplasia type 1 (MEN1) is a rare inherited syndrome, caused by heterozygote inactivating mutation of the MEN1 tumor suppressor gene, and characterized by the development of mult...
2 CitationsSource
#1Cheng Han NgH-Index: 6
#2Yip Han ChinH-Index: 3
Last. Chin Meng Khoo (NUS: National University of Singapore)H-Index: 17
view all 7 authors...
PURPOSE Primary hyperparathyroidism (PHPT) is common condition, affecting people of all ages and is mainly treated with parathyroidectomy. Cinacalcet has been widely used in secondary or tertiary hyperparathyroidism, but the use of cinacalcet in PHPT is less clear. METHODS Searches were conducted in Medline and Embase for cinacalcet use in PHPT from induction to 10th April 2020. Articles and conferences abstracts describing the use of cinacalcet for PHPT in prospective or retrospective cohorts a...
3 CitationsSource
#1Barbara Altieri (University of Würzburg)H-Index: 16
#2Carla Di DatoH-Index: 6
Last. Annamaria ColaoH-Index: 116
view all 9 authors...
Patients affected by gastroenteropancreatic–neuroendocrine tumors (GEP–NETs) have an increased risk of developing osteopenia and osteoporosis, as several factors impact on bone metabolism in these patients. In fact, besides the direct effect of bone metastasis, bone health can be affected by hormone hypersecretion (including serotonin, cortisol, and parathyroid hormone-related protein), specific microRNAs, nutritional status (which in turn could be affected by medical and surgical treatments), a...
4 CitationsSource
#1M. VialonH-Index: 3
#2Rachel DesailloudH-Index: 15
Last. Philippe CaronH-Index: 51
view all 3 authors...
Resume La neoplasie endocrinienne multiple de type 1 (NEM1) est liee a des mutations du gene de la menine ; elle est de transmission autosomique dominante. La prevalence est d’environ 1/30 000 et la penetrance est elevee. Il n’y a pas de correlation genotype-phenotype. Ce syndrome hereditaire se caracterise par la presence de tumeurs du systeme endocrine (parathyroides, pancreas endocrine, hypophyse et surrenales). D’autres atteintes ont egalement ete decrites (tumeur carcinoide bronchique et th...
1 CitationsSource
#1Crystal Kamilaris (NIH: National Institutes of Health)H-Index: 4
#2Constantine A. Stratakis (NIH: National Institutes of Health)H-Index: 107
Multiple endocrine neoplasia type 1 (MEN1) is a rare hereditary tumor syndrome inherited in an autosomal dominant manner and characterized by a predisposition to a multitude of endocrine neoplasms primarily of parathyroid, enteropancreatic, and anterior pituitary origin, as well as nonendocrine neoplasms. Other endocrine tumors in MEN1 include foregut carcinoid tumors, adrenocortical tumors, and rarely pheochromocytoma. Nonendocrine manifestations include meningiomas and ependymomas, lipomas, an...
38 CitationsSource
#1Alexander T. Deng (Guy's and St Thomas' NHS Foundation Trust)
#2Louise Izatt ('KCL': King's College London)H-Index: 2
Purpose of the Review There has been a significant expansion in our knowledge of inherited endocrine neoplasia. This review describes syndromic and non-syndromic hereditary endocrine tumours, associated genetic testing, and progress in the management of the disease.
#1Francesca MariniH-Index: 23
#2Francesca GiustiH-Index: 15
Last. Maria Luisa Brandi (UniFI: University of Florence)H-Index: 88
view all 3 authors...